Study |
Criteria to define CSCs |
Percentage (n) |
Pathological subtype |
| (Ignatova et al., 2002) |
Isolation of clonogenic cells |
80 % (n=10) |
Anaplastic astrocytoma
and recurrent malignant GBM |
| (Brehar et al., 2009) |
Expression of stem cell markers (nestin, CD133) |
100 % (n=1) |
Glioblastoma (1) |
| (Galli et al., 2004) |
capacity for long-term proliferation, self-renewal, multipotency and their tumorigenicity |
100 % (n=10) |
Glioblastoma (6), Medulloblastoma (4), |
| (Singh et al., 2003) |
Self-renewal, proliferation, and lineage restricted
differentiation |
100% (n=14) |
Medulloblastoma (8), Pilocytic astrocytoma (3), Grade 2 astrocytoma (1), Ependymoma (1), Ganglioglioma (1) |
| (Yuan et al., 2004 ) |
Formation of tumor spheres, self-renewal capacitiy, expression of
NSC markers as well as lineage markers, multipotentiality, capability of forming tumors in vivo |
100 % (n=6) |
Glioblastomas |
| (Bao et al., 2006) |
Neurosphere formation and tumorigencity |
100 % (n=3) |
Primary gliomas |
| (Yi et al., 2007) |
Formation of tumor spheres, Tumorigenicity |
100 % (n=3) |
anaplastic oligoastrocytoma |
| (Kelly et al., 2009) |
Formation of tumor spheres, self-renewal capacitiy, multilineage Differentiation |
73 % (n=11) |
Glioblastomas |
|